Pathway OME Launches Sport iQ

SAN DIEGO--(BUSINESS WIRE)-- Pathway Genomics OME, a leader in the DNA testing industry, is launching a new test focused on exercise performance for their direct-to-consumer (DTC) line of products. Sport iQ ($149) is the newest and most advanced exercise genetic test available, which gives the consumer an in-depth look into how genes play a role in the body’s response to exercise and other metabolic components. Along with the test report, the user will receive a detailed exercise plan based on the report results; and also the ability to have their results used for ongoing sports-related genomic trials.

“Sport iQ was in part designed with Pathway-generated data from the largest ever exome-genomic exercise study of 1200 elite marathon athletes, of which we are continually analyzing by Machine Learning and publishing new insights,” says Dr. Michael Nova, Chief Innovative Officer and company founder. [Ref: https://www.biorxiv.org/content/early/2018/07/16/369066]

Learning how your body responds to exercise is paramount to overall preventative health and human performance. Most people go through years of trial and error before figuring out what is best for their unique metabolism. By using the power of your DNA, this test acts as a blueprint guide to help you understand what your body is made for at the most fundamental level possible.

From the beginner to the stay-at-home mom, or the elite athlete, this test can provide the consumer at any level with personalized knowledge to begin a new journey towards better health, wellness, and optimal performance.

About Pathway Genomics

Since its founding in 2008, Pathway Genomics (www.pathway.com) has become known for its dedication to innovation – making it a leader in the commercial healthcare industry. Focusing on providing users with the most validated and personalized healthcare information delivered to any device, the company’s program with IBM data is the first of its kind to merge artificial intelligence (AI) and deep learning with precision medicine, applicable to both consumers and providers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180814005188/en/